Karyopharm Therapeutics Lowered to Market Perform at Oppenheimer (KPTI)
Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by equities researchers at Oppenheimer from an “outperform” rating to a “market perform” rating in a research report issued on Monday, TheFlyOnTheWall.com reports.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 2.70% during mid-day trading on Monday, hitting $41.83. The stock had a trading volume of 877,927 shares. Karyopharm Therapeutics has a 52-week low of $15.50 and a 52-week high of $47.98. The stock has a 50-day moving average of $34.27 and a 200-day moving average of $32.23. The company’s market cap is $1.245 billion.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.46) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.47) by $0.01. On average, analysts predict that Karyopharm Therapeutics will post $-2.00 earnings per share for the current fiscal year.
In other Karyopharm Therapeutics news, CEO Michael Kauffman unloaded 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $42.50, for a total transaction of $8,500,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.